Press release
Adrenocortical Carcinoma Treatment Pipeline Shows Strong Momentum as 3+ Pharma Companies in the Race | DelveInsight
Adrenocortical Carcinoma Pipeline
Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Adrenocortical Carcinoma Pipeline Report
• In December 2025, UNICANCER conducted a phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-resectable metastatic or locally advanced non-colorectal and non-endometrial cancers compared to the standard of care chemotherapy.
• DelveInsight's Adrenocortical Carcinoma Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Adrenocortical Carcinoma treatment.
• The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
• Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Adrenocortical Carcinoma Overview
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy originating from the adrenal cortex, the outer layer of the adrenal glands responsible for producing steroid hormones such as cortisol, aldosterone, and androgens. Although ACC accounts for a small fraction of all cancers, its clinical complexity and high morbidity make it a critical area of focus in oncology research and therapeutic development.
Adrenocortical Carcinoma Emerging Drugs Profile
• CY-101: Cytovation
CyPep-1 is a proprietary first-in-class targeted tumor membrane immunotherapy engineered to selectively target cancer cells. Administered by intratumoral injection, CyPep-1 eliminates cancer cells by forming pores in the plasma membrane, releasing cancer specific antigens to the immune system, promoting an inflammatory microenvironment, and inducing a systemic, tumor-specific immune response. A synthetic peptide, CyPep-1 has been designed for easy and scalable manufacturing and is highly stable - an uncommon feature in these molecules. Currently, the drug is in Phase II stage of its clinical trial as per the Company Pipeline for the treatment of Adrenocortical Carcinoma.
The Adrenocortical Carcinoma Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
• Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market
Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Adrenocortical Carcinoma Drugs- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Adrenocortical Carcinoma Companies
Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Adrenocortical Carcinoma Market Report
• Coverage- Global
• Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
• Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
• Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Introduction
2. Executive Summary
3. Adrenocortical Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Adrenocortical Carcinoma- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Ipilimumab: Bristol-Myers Squibb
9. Drug profiles in the detailed report.....
10. Early Stage Products (Phase I)
11. Relacorilant: Corcept Therapeutics
12. Preclinical and Discovery Stage Products
13. Drug name: Company name
14. Drug profiles in the detailed report.....
15. Inactive Products
16. Adrenocortical Carcinoma Key Companies
17. Adrenocortical Carcinoma Key Products
18. Adrenocortical Carcinoma- Unmet Needs
19. Adrenocortical Carcinoma- Market Drivers and Barriers
20. Adrenocortical Carcinoma- Future Perspectives and Conclusion
21. Adrenocortical Carcinoma Analyst Views
22. Adrenocortical Carcinoma Key Companies
23. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenocortical Carcinoma Treatment Pipeline Shows Strong Momentum as 3+ Pharma Companies in the Race | DelveInsight here
News-ID: 4340201 • Views: …
More Releases from DelveInsight Business Research LLP
Myasthenia Gravis Clinical Trial Pipeline Expands as 20+ Companies Driving Innov …
DelveInsight's "Myasthenia Gravis Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Peripheral Nerve Injuries Market Size (7MM) was ~USD 2.4 Billion in 2023 and It …
(Albany, USA) DelveInsight's "Peripheral Nerve Injury Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Peripheral Nerve Injury, historical and forecasted epidemiology as well as the Peripheral Nerve Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Peripheral Nerve Injury Market. Download sample report @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Peripheral Nerve Injury Market…
Restrictive Cardiomyopathy Market Size (7MM) was ~USD 26.09 Million in 2023 and …
DelveInsight's "Restrictive Cardiomyopathy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Restrictive Cardiomyopathy, historical and forecasted epidemiology and the Restrictive Cardiomyopathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Restrictive Cardiomyopathy Market with DelveInsight's In-Depth Report @ Restrictive Cardiomyopathy Market Size- https://www.delveinsight.com/sample-request/restrictive-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Restrictive…
Malignant Ascites Market Size (7MM) was ~USD 1,990 million in 2020, which is ant …
DelveInsight's "Malignant Ascites Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Malignant Ascites, historical and forecasted epidemiology as well as the Malignant Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover Key Insights into the Malignant Ascites Market with DelveInsight's In-Depth Report @ Malignant Ascites Market Size- https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Malignant Ascites Market Report
• In December 2025,…
More Releases for Adrenocortical
Adrenocortical Carcinoma Treatment Market Diagnostic Improvements and Evolving T …
The Adrenocortical Carcinoma (ACC) Treatment Market is growing steadily as improvements in diagnostic imaging, surgical oncology, and targeted therapies enhance the management of this rare but aggressive endocrine malignancy. ACC often presents late and requires multimodal treatment including surgery, adrenalectomy, mitotane therapy, chemotherapy, and emerging immunotherapies. Rising clinical awareness, improved diagnostic accuracy, and expansion of cancer centers specializing in rare tumors are fueling demand for effective ACC treatments.
Download Full PDF…
Adrenocortical Hormones API Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Drugs Market Overview: Growth, Share, Value, Size, and …
The global Adrenocortical Carcinoma Drugs market is projected to reach approximately USD 0.85 billion by 2033, growing at a compound annual growth rate (CAGR) of around 7.2% from 2025 to 2033.
Adrenocortical Carcinoma Drugs Market Overview
The global Adrenocortical Carcinoma (ACC) drugs market is experiencing growth, driven by the increasing incidence of this rare endocrine malignancy and advancements in therapeutic approaches. ACC is characterized by aggressive tumor behavior and limited treatment options,…
Adrenocortical Hormones API Market Survey Detailed Analysis and Forecast 2024-20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Treatment: Challenges, Advances, and Market Dynamics
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer originating in the adrenal cortex, the outer layer of the adrenal glands. These glands, located above the kidneys, are responsible for producing hormones that regulate a variety of bodily functions, such as metabolism, blood pressure, and immune response. ACC is often diagnosed at an advanced stage due to its asymptomatic early course, and treatment options are limited. In this…
Adrenocortical Hormones API Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Adrenocortical Hormones API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Adrenocortical Hormones APImarket by key players, product type, applications and regions,etc.
The main objective of this market research is to help the readers understand the structure of Adrenocortical Hormones APImarket, market definition, overview, industry opportunities…
